机器学习分层分析度普利尤单抗治疗特应性皮炎患者的面部残留红斑
本研究基于2018年7月至2021年7月的回顾性数据,通过层次聚类将度普利尤单抗治疗的特应性皮炎患者按面部红斑病程分为早期缓解、低缓解和持续残留三组,并利用LightGBM构建预测模型。二分类模型区分早期缓解与持续残留患者的准确率为89.10%,AUC为0.862;与面部红斑严重程度相关的八个主要因素包括年龄、性别、乳酸脱氢酶、免疫球蛋白E、嗜酸性粒细胞计数、白细胞计数、桤木过敏和雪松过敏。
要点
- 层次聚类可识别度普利尤单抗治疗后面部红斑的三种不同病程亚型。
- LightGBM模型区分早期缓解与持续残留的准确率达89.10%,AUC为0.862。
- 年龄、性别、LDH、IgE、嗜酸性粒细胞、白细胞及过敏史与红斑严重程度相关。
核心结论
- 研究通过无监督学习识别出三种面部红斑病程聚类,并构建了优于随机预测的分类模型。
- 关键因素的识别为AI驱动的预后模型奠定基础,有望改善特应性皮炎个性化治疗选择。
研究设计与样本
- 回顾性研究,收集2018年7月至2021年7月的数据进行分析。
- 采用层次聚类根据面部红斑病程将患者分为早期缓解、低缓解和持续残留三组。
- 使用LightGBM监督梯度提升决策树算法构建预测模型,纳入治疗前后检查等人口学与临床特征。
- 模型性能以准确率和受试者工作特征曲线下面积(AUC)评估。
主要发现
- 二分类模型区分早期缓解与持续残留患者的准确率为89.10%,AUC为0.862。
- 与面部红斑严重程度相关的八个主要因素为年龄、性别、乳酸脱氢酶(LDH)、免疫球蛋白E(IgE)、嗜酸性粒细胞计数、白细胞计数、桤木过敏和雪松过敏。
临床怎么用
- 可依据年龄、性别、LDH、IgE、嗜酸性粒细胞计数、白细胞计数及过敏史等因素对度普利尤单抗治疗患者进行面部红斑风险分层。
- 基于机器学习的预测模型有助于早期识别可能持续残留面部红斑的患者,辅助个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persistent facial erythema represents a significant complication in atopic dermatitis (AD) patients undergoing treatment with dupilumab. Stratifying patients based on the erythema course is crucial for elucidating heterogeneous phenotypes and facilitating advanced drug efficacy predictions. OBJECTIVES: This study aimed to identify factors associated with facial erythema severity in dupilumab-treated AD patients and to establish a prediction model for drug response based on the identified factors. METHODS: Data from a retrospective study conducted between July 2018 and July 2021 were collected and analysed. Patients were categorized into three groups via hierarchical clustering based on the course of facial erythema: early remission, low remission and persistent residual. LightGBM, a supervised gradient boosting decision tree algorithm, was employed to discern group differences and construct a prediction model. The model incorporated patient demographic and clinical profiles, including pre- and post-treatment examinations. The model's performance was evaluated using accuracy and the area under the receiver operating characteristic curve (AUC). RESULTS: The binary classification model demonstrated an accuracy of 89.10% and an AUC of 0.862 when distinguishing between early remission and persistent residual patients. The eight prominent factors associated with facial erythema severity included age, sex, lactate dehydrogenase (LDH), immunoglobulin E (IgE), eosinophil count, white blood cell count, Alnus allergy and cedar allergy. CONCLUSIONS: This study has two main significances: first, three clusters were identified through unsupervised learning; second, a classification model was constructed that proved more accurate than random prediction. The stratification and identification of crucial factors associated with residual facial erythema in dupilumab-treated AD patients lay the foundation for AI-powered prognostic models. This groundwork provides a substantial basis for enhancing future medical AI support in AD treatment selection, potentially improving personalized treatment approaches and outcomes.
引用
- Ashizaki K, Ishikawa T, Nomura Y, et al. Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning. J Eur Acad Dermatol Venereol. 2024. PMID: 38407422. doi:10.1111/jdv.19909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。